Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Genodx Pty Ltd. currently maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, CARLA J MYERS, who is the busiest examiner for the portfolio. The prosecution is situated within 1 distinct art unit, indicating a highly focused and centralized approach to the company's current intellectual property development.
With only 1 pending office action, the company's immediate prosecution resources are dedicated to a single case. CARLA J MYERS is responsible for 1 pending action, making CARLA J MYERS the sole point of contact for the company's active matters before the patent office. This concentration in the Biotechnology & Pharmaceuticals area allows for a specialized strategy tailored to the specific expectations of this examiner and art unit.
The data shows that there are no other pending actions or 1 distinct examiner involved in the company's current portfolio. This simplicity in the prosecution landscape means that the company can focus entirely on the requirements of the examiner within the 1 distinct art unit. This streamlined profile is efficient for managing a single active priority in a complex technical field like Biotechnology & Pharmaceuticals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MYERS, CARLA J | 1 | 49.3% | +46.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705818 | BIOMARKERS AND USES THEREFOR | MYERS, CARLA J | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705818 | BIOMARKERS AND USES THEREFOR | MYERS, CARLA J | 1682 | DP | Non-Final OA | — | Pending | Apr 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial